Suven Life Sciences has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Wednesday, May 13, 2026, in compliance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice, dated May 06, 2026, was issued by Company Secretary & Compliance Officer K. Sangeetha Laxmi.

Board Meeting Agenda

The Board meeting has been convened to consider and approve the Audited Financial Results of the company for the quarter and financial year ended March 31, 2026, on both a standalone and consolidated basis, along with related matters. The key details of the scheduled meeting are outlined below:

Trading Window Closure

In accordance with the company's Code of Conduct for Prohibition of Insider Trading in Securities, Suven Life Sciences has also disclosed the status of its trading window. The trading window closure timeline is as follows:

The trading window will remain closed until May 15, 2026 (both days inclusive), which is 48 hours after the expected declaration of the financial results on May 13, 2026.

Regulatory Compliance

The intimation was submitted to both BSE Limited and the National Stock Exchange of India Limited, fulfilling the company's disclosure obligations under applicable SEBI regulations. The notice was digitally signed by K. Sangeetha Laxmi, Company Secretary & Compliance Officer, on May 06, 2026.

Suven Life Sciences is headquartered at SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, Hyderabad – 500034, Telangana, India.

Suven Life Sciences Limited has responded to surveillance queries from both BSE and NSE regarding unusual price and volume movements in its stock, clarifying that no material events are pending disclosure that could justify the recent market activity.

Exchange Surveillance Response

The Hyderabad-based pharmaceutical company issued its clarification on April 8, 2026, in response to surveillance emails received from both exchanges on April 7, 2026. The company addressed specific reference numbers from both exchanges regarding the price movement concerns.

Company's Position on Price Movement

Suven Life Sciences emphasized its compliance with disclosure requirements, stating it has been regularly notifying stock exchanges of all events and information falling under SEBI LODR Regulation 30. The company confirmed it currently has no material announcements or events due for notification that could influence its stock's price or volume behavior.

The management attributed the recent price and volume movements to market speculation, declining to provide additional commentary on the development. This response indicates the company believes the stock movement is not based on any fundamental business developments or undisclosed material information.

Regulatory Compliance Framework

The company reiterated its commitment to transparency by confirming regular compliance with SEBI LODR Regulation 30, which mandates disclosure of material events and information that could impact stock performance. The clarification document was signed by Company Secretary K. Sangeetha Laxmi and has been made available on both exchange websites and the company's official website for public information.

Corporate Communication

The formal response demonstrates Suven Life Sciences' proactive approach to addressing market surveillance concerns and maintaining regulatory compliance. The company requested both exchanges to disseminate the clarification on their websites while simultaneously uploading the information on its corporate website to ensure broad accessibility for investors and stakeholders.